ORIGINAL ARTICLE Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents Samantha M. Olson, Margaret M. Newhams, Natasha B. Halasa, et al N Engl J Med 2022; 386:713-723DOI: 10.1056/NEJMoa2117995 Abstract BACKGROUND The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United...

Surviving Sepsis Campaign Guidelines and Individualised Care Sepsis is a major cause of death in the ICU. It is a complex disease, and treatment is typically guided by evidence-based guidelines. However, it is important to remember that guidelines provide a systematic approach to patient evaluation and treatment decisions, but they are not a compilation of truth. The Surviving Sepsis Campaign (SSC) Guidelines are the most reliable guidelines used by the intensiv...

Original Investigation November 17, 2021 Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant: A Randomized Clinical Trial Kamrouz Ghadimi, Jhaymie Cappiello, Mary Cooter-Wright, et al JAMA Surg. 2022;157(1):e215856. doi:10.1001/jamasurg.2021.5856 Abstract Importance  Inhaled nitric oxide (iNO) is commonly administered for selectively inhaled pulmonary vasodilation and prevention of oxidative injury after lung transplant (LT). Inhal...

COMMENT| VOLUME 399, ISSUE 10325, P609-610, FEBRUARY 12, 2022 Another piece in the COVID-19 treatment puzzle Cristina Mussini, Alessandro Cozzi-Lepri Lancet 2022; 399: 609-610 DOI:https://doi.org/10.1016/S0140-6736(22)00154-4 A new study1 from the RECOVERY Collaborative Group adds another piece to the puzzle of severe COVID-19 therapy. The RECOVERY trials have been pivotal in providing evidence on the efficacy of compounds within current trea...

Application of Artificial Intelligence in the ICU Artificial Intelligence (AI) holds great promise in critical care. Vast amounts of data are regularly collected in intensive care units, making ICUs the perfect environment for deploying machine-learning techniques. AI in ICUs can have several applications. For example, when determining the short and long-term outcomes of different interventions, a well-designed ICU system could provide significant support in the...

Original Investigation January 18, 2022 Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial Jeffrey S. Berger, Lucy Z. Kornblith, Michelle N. Gong, et al JAMA. 2022;327(3):227-236. doi:10.1001/jama.2021.23605 Abstract Importance  Platelets represent a potential therapeutic target for improved clinical...

COMMENT|ONLINE FIRST Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19 Adrienne E Shapiro, Rachel A Bender Ignacio Lancet Infect Dis Published:December 23, 2021 DOI:https://doi.org/10.1016/S1473-3099(21)00762-3 The research community has responded to the COVID-19 pandemic with innovative platform trials to address the need for rapid evaluation of novel agents using a common protocol, among them being RECOVERY,1&nbs...

ARTICLES|ONLINE FIRST Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021 COVID-19 National Preparedness Collaborators Lancet Published:February 01, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00172-6 Summary Background National rates of COVID-19 infection and fatality have varied dramatically since the o...

2030: Projections for the Emergency Medicine Physician Workforce Over the last few decades, the emergency physician workforce has undergone a dramatic transformation. There was a time when most physicians working in the emergency department had not completed residency training in emergency medicine. This began around 1970. Today, there are 273 emergency medicine residences accredited by the Accreditation Council for Graduation Medical Education (ACGME). While em...

ARTICLES|ONLINE FIRST Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group Lancet Infect Dis Published:December 23, 2021DOI:https://doi.org/10.1016/S1473-3099(21)00751-9 Summary Background We aimed to assess the efficacy and safety of two neutralising mono...